Abstract library

106 results for "non-functional kidney".
#238 Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?
Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#2684 Tumour-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumour Patients after Curative Resection
Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) are steadily increasing in prevalence and present several clinical challenges.
Conference: 17th Annual ENETS Conference (2020)
Category: Biomarkers
Presenting Author: Dr Wuhu Zhang
Authors: Zhang W, Wang W
#1388 Nephrotoxicity after PRRT with 177Lu-DOTA-Octreotate
Introduction: Renal toxicity may occur after Peptide Receptor Radionuclide Therapy (PRRT). Risk factors have been identified for renal toxicity after 90Y based PRRT.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Hendrik Bergsma
#1787 Towards Personalizing PRRT with [177Lu]-Dotatate to Minimise Renal Toxicity in Neuroendocrine Tumour Patients
Introduction: The kidney is a dose-limiting organ in [177Lu]-Dotatate PRRT (Lutate) and thus renal function is an important prescribing consideration for NET patients. The effect of baseline renal function on kidney absorbed dose is unclear.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Enid Eslick
#1651 Renal Neuroendocrine Tumors (rNETs): A Single-Center Experience.
Introduction: rNETs are rare tumors and little is known about their natural history.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Dr. Thorvardur Halfdanarson
Keywords: Renal, Kidney, NET, Carcinoid
#1606 Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis
Introduction: The slow-growing character of neuroendocrine tumors (NET) makes it difficult to assess treatment impact on tumor growth.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Frank van Fraeyenhove
#1797 An Open-Label Phase II Study to Evaluate the Efficacy and Safety Of PDR001 in Patients with Advanced Well-Differentiated Non-Functional NET of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti-PD-1 and anti-PD-L1, have become established treatment (tx) options in various solid tumors. However, there is a paucity of data on checkpoint inhibitors in NET. In a phase I trial of PDR001 (mAb checkpoint inhibitor targeting PD-1) conducted in patients (pts) with multiple solid tumor types, a pt with histologically confirmed metastatic atypical pulmonary carcinoid demonstrated a RECIST-based tumor response and clinical benefit.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: James C Yao
Authors: Yao J C, Fazio N, Pavel M, Strosberg J, ...
Keywords: PDR001, immunotherapy, NET
#808 Characteristics and Determinants of Long-Term Outcome for Resectable Sporadic Non-Functional Pancreatic Neuroendocrine Tumors (NF-PNETs): Updated 16-year Experience from Two Large Chinese Centers
Introduction: Non-functional pancreatic neuroendocrine tumors (NF-PNETs) are increasingly recognized with unique biology.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: M.D. Xu Han
Authors: Jin G, Han X, Jin D, Hu X, ...
Keywords: NF-PNETs
#1050 Recurrent Disease After Curative Pancreatic Resection for Patients with Non-Functional Neuroendocrine Tumor; Identify the High Risk Patient
Introduction: Since the overall favourable survival, detection of recurrent disease is one of the main goals during follow up in patients with resected pancreatic neuroendocrine tumors (pNET).
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Anneke Jilesen
Keywords: NF
#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC
Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Sofie M.D.A. Van Binnebeek
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team